Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients

Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Zhao(Wenzhou Hospital of Traditional Chinese Medicine), Xiangning Liu(First Affiliated Hospital of Jinan University), Xiaoyan Liu(Capital Medical University), Li Zhang(Gdańsk Medical University), Dongming Zhang(Heilongjiang Bayi Agricultural University), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuequan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College)
Clinical Lung Cancer
December 27, 2022
10.1016/j.cllc.2022.12.003
Cited by 16

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
|The Lancet Oncology|2012|228
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
|PLoS ONE|2015|206